William McDowall Wells is Director at Valeant Pharmaceuticals International, Inc. (VRX). They have made 2 open-market trades across 1 company since 2010, most recently 2014-11-21.
CIK 0001476860
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ACAD | SELL · 10b5-1 | 2014-11-21 | 2014-11-21 | $29.00 | $168K | -33.1% | +0.1% | +0.1% |
| ACAD | SELL · 10b5-1 | 2014-09-12 | 2014-09-16 | $29.15 | $268K | -33.1% | +0.1% | +0.1% |
| ACAD | SELL · 10b5-1 | 2014-06-09 | 2014-06-10 | $23.03 | $345K | -33.1% | +0.1% | +0.1% |
| VRX | SELL | 2010-12-06 | 2010-12-08 | $28.13 | $14.3M | -12.8% | +0.4% | +0.4% |
| VRX | SELL | 2010-11-09 | 2010-11-12 | $25.86 | $9.7M | -12.8% | +0.4% | +0.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.